Talecris Biotherapeutics (TLCR) IPO Prices at $19

October 1, 2009 6:59 AM EDT

Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) announced the pricing of its initial public offering of 50,000,000 shares of its common stock at a price of $19.00 per share, the middle of the expected $18-$20 range.

Shares are expected to open on the Nasdaq today under the ticker symbol "TLCR."

Of the shares being offered, 28,947,368 are being offered by the Company and 21,052,632 are being offered by the selling stockholder, Talecris Holdings, LLC. Talecris Holdings, LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and limited partnerships affiliated with Ampersand Ventures.

Talecris intends to use the net proceeds of the offering to repay amounts owed under its First Lien Term Loan Credit Agreement and Second Lien Term Loan Credit Agreement. Talecris will not receive any of the proceeds from the offering of the common stock by the selling stockholder.

Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co., Citigroup Global Markets Inc. and J.P. Morgan Securities Inc. are acting as joint book-running managers for the offering.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology and hemostasis.

Related Categories

IPOs
Trader Talk

Stocks Mentioned

Related Entities

• Cerberus Capital
• JPMorgan
• Citi
• Morgan Stanley

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?